FDA Approves Genentechs Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer

Approval based on survival benefit of Tecentriq in combination with Avastin paclitaxel and carboplatin chemotherapy in people with metastatic nonsquamous nonsmall cell lung cancer NSCLC with no EGFR or ALK genomic tumor aberrations...